Enzyme Engineering

& Industrial Fermentation

Enzymes are widely used as biocatalysts in the production or processing of a wide range of products including food, beverages, animal feeds, detergents, pharmaceuticals and textile products. Naturally occurring enzymes are often unstable or perform sub-optimally when moved from the biological to the industrial sphere.

Therefore, since the advent of protein engineering there have been efforts to improve these enzyme properties, and even to devise enzymes with novel specificities capable of producing types or quantities of metabolites not normally achievable in natural products. Such improvements or changes can often be challenging: enzyme activity depends on specific and highly complex structures, sometimes formed from multiple protein components, and requiring associated factors or metal ions to operate. Frequently, enhancing one desirable property comes at the cost of impairing another.

Mewburn Ellis has a long history of working with our clients in this fast-moving and competitive field. For example, we’ve been involved in protecting the ground-breaking innovations on the serine protease subtilisin (used for example in detergents and in food processing) since 1980s, and in multiple other enzymes in different fields such as brewing, biofuels and biopolymers. The Mewburn team has regularly and successfully defended patents covering our clients’ enzyme technologies at the EPO and assisted them in enforcing those patents before national courts. Engineered enzymes are typically produced in host species such as bacteria, yeasts and filamentous fungi and we also have many years’ experience in dealing with the fermentation technologies used for growing these microorganisms, and recovering the enzymes from them, whether at laboratory or industrial scale.

As more and more powerful computation tools are developed for determining and modelling protein structures, so protein engineers are increasingly able to analyse the structure-function characteristics for rationale design of novel enzymes, which can then be tested in large scale functional screening processes. Once again, our specialised team here is able to assist at our clients with obtaining protection for their intellectual property in the latest bioinformatics innovations in the enzyme space.

Open pages of Green IP Report

Green IP Report

Patents are both a driver and a barometer of innovation

Our report examines the role of patents in making innovative ‘green’ technologies into a reality as well as how the patent landscape can be used to identify opportunities for partnering, collaboration and investment.

We share our enthusiasm and admiration for commercially-focused innovation across a diverse range of technologies, from repurposing carbon dioxide to make protein-rich foods, to the multi-faceted approach to a circular plastics economy. We also discuss the tantalising prospect of AI-mediated renewable energy supply, and the harnessing of battery tech from the EV boom to drive energy efficiency in consumer devices. This report reflects our passion for technology solutions that tackle our shared global challenge.

Download the Report

Read our Blogs

Patent Strategies for Cell-based Therapeutics

Patent Strategies for Cell-based Therapeutics

by Nick Sutcliffe

Securing robust patent protection for cell-based therapeutics presents unique challenges, particularly before the European Patent Office (EPO). As the field of regenerative medicine and cell therapy ...

Mitochondria: the secret to regenerating human tissue?

Mitochondria: the secret to regenerating human tissue?

by Eliot Ward

Istesso co-founder Lisa Patel is researching how to regenerate and repair tissue by modulating mitochondria. The method has the potential to treat multiple diseases of ageing, such as arthritis, ...

Bispecific antibodies: A new way to combat drug resistance

Bispecific antibodies: A new way to combat drug resistance

by Tanis Keirstead

Biotech veteran Dr Rob Arathoon is pioneering a new way to counteract multi-drug resistance in cancer using bispecific antibodies. He explains his work.

Ozempic and the Anti-Ageing Opportunity

Ozempic and the Anti-Ageing Opportunity

by Katherine Collins

Semaglutide, a GLP-1 receptor agonist (GLP-1RA) best known by its brand names Ozempic and Wegovy, has already reshaped the treatment landscape for type 2 diabetes and obesity. However, compelling new ...

Are proprietors out of luck on appeal? It’s all in the reporting

Are proprietors out of luck on appeal? It’s all in the reporting

by Emily Garnett

The 2024 EPO Boards of Appeal Annual Report has recently been published, and, once again, it’s the appeal success statistics that are drawing the attention of patent applicants, proprietors, and ...

Most Active Visible Opponents at the EPO in 2024

Most Active Visible Opponents at the EPO in 2024

by Katherine Green

An opposition is a formal request for revocation of a patent, which can be filed by a third party within nine months of patent’s grant by the European Patent Office.

Learn More
Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.